These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27316377)

  • 1. Nek2 siRNA therapy using a portal venous port-catheter system for liver metastasis in pancreatic cancer.
    Kokuryo T; Hibino S; Suzuki K; Watanabe K; Yokoyama Y; Nagino M; Senga T; Hamaguchi M
    Cancer Sci; 2016 Sep; 107(9):1315-20. PubMed ID: 27316377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor Effect of Oleoyl-siRNA against Pancreatic Cancer Using a Portal Vein Infusion Liver-Metastatic Mouse Model.
    Kubo T; Yanagihara K; Nishimura Y; Iino Y; Komatsu T; Tansou R; Mihara K; Seyama T
    Mol Pharm; 2024 Oct; 21(10):5115-5125. PubMed ID: 39279440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma.
    Kokuryo T; Senga T; Yokoyama Y; Nagino M; Nimura Y; Hamaguchi M
    Cancer Res; 2007 Oct; 67(20):9637-42. PubMed ID: 17942892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin.
    Suzuki K; Kokuryo T; Senga T; Yokoyama Y; Nagino M; Hamaguchi M
    Cancer Sci; 2010 May; 101(5):1163-9. PubMed ID: 20345485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatoma cell functions modulated by NEK2 are associated with liver cancer progression.
    Wu SM; Lin SL; Lee KY; Chuang HC; Feng PH; Cheng WL; Liao CJ; Chi HC; Lin YH; Tsai CY; Chen WJ; Yeh CT; Lin KH
    Int J Cancer; 2017 Apr; 140(7):1581-1596. PubMed ID: 27925179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Administration of Small Interfering RNA Targeting Human Nestin Inhibits Pancreatic Cancer Cell Proliferation and Metastasis.
    Matsuda Y; Ishiwata T; Yoshimura H; Yamashita S; Ushijima T; Arai T
    Pancreas; 2016 Jan; 45(1):93-100. PubMed ID: 26335012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nek2 as a novel molecular target for the treatment of breast carcinoma.
    Tsunoda N; Kokuryo T; Oda K; Senga T; Yokoyama Y; Nagino M; Nimura Y; Hamaguchi M
    Cancer Sci; 2009 Jan; 100(1):111-6. PubMed ID: 19038001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lentivirus-mediated shRNA interference targeting vascular endothelial growth factor inhibits angiogenesis and progression of human pancreatic carcinoma.
    Zhao X; Zhu DM; Gan WJ; Li Z; Zhang JL; Zhao H; Zhou J; Li DC
    Oncol Rep; 2013 Mar; 29(3):1019-26. PubMed ID: 23254994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis.
    Yan Z; Ohuchida K; Zheng B; Okumura T; Takesue S; Nakayama H; Iwamoto C; Shindo K; Moriyama T; Nakata K; Miyasaka Y; Ohtsuka T; Mizumoto K; Oda Y; Hashizume M; Nakamura M
    J Cancer Res Clin Oncol; 2019 May; 145(5):1147-1164. PubMed ID: 30770989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells.
    Lee J; Gollahon L
    Int J Oncol; 2013 Mar; 42(3):839-47. PubMed ID: 23340795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-regulation of NEK2 by microRNA-128 methylation is associated with poor prognosis in colorectal cancer.
    Takahashi Y; Iwaya T; Sawada G; Kurashige J; Matsumura T; Uchi R; Ueo H; Takano Y; Eguchi H; Sudo T; Sugimachi K; Yamamoto H; Doki Y; Mori M; Mimori K
    Ann Surg Oncol; 2014 Jan; 21(1):205-12. PubMed ID: 24046120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo.
    Pan X; Zhu Q; Sun Y; Li L; Zhu Y; Zhao Z; Zuo J; Fang W; Li K
    Int J Mol Med; 2015 Apr; 35(4):995-1002. PubMed ID: 25672594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gold nanoclusters-assisted delivery of NGF siRNA for effective treatment of pancreatic cancer.
    Lei Y; Tang L; Xie Y; Xianyu Y; Zhang L; Wang P; Hamada Y; Jiang K; Zheng W; Jiang X
    Nat Commun; 2017 Apr; 8():15130. PubMed ID: 28440296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NEK2 Is an Effective Target for Cancer Therapy With Potential to Induce Regression of Multiple Human Malignancies.
    Kokuryo T; Yokoyama Y; Yamaguchi J; Tsunoda N; Ebata T; Nagino M
    Anticancer Res; 2019 May; 39(5):2251-2258. PubMed ID: 31092416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1.
    Zhang X; Huang X; Xu J; Li E; Lao M; Tang T; Zhang G; Guo C; Zhang X; Chen W; Yadav DK; Bai X; Liang T
    Nat Commun; 2021 Jul; 12(1):4536. PubMed ID: 34315872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
    Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN
    Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer.
    Zeng YR; Han ZD; Wang C; Cai C; Huang YQ; Luo HW; Liu ZZ; Zhuo YJ; Dai QS; Zhao HB; Liang YX; Zhong WD
    BMC Urol; 2015 Aug; 15():90. PubMed ID: 26320076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells.
    Rivera-Rivera Y; Marina M; Jusino S; Lee M; Velázquez JV; Chardón-Colón C; Vargas G; Padmanabhan J; Chellappan SP; Saavedra HI
    Sci Rep; 2021 Apr; 11(1):9016. PubMed ID: 33907253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.
    Wang J; Lu Z; Wang J; Cui M; Yeung BZ; Cole DJ; Wientjes MG; Au JL
    J Control Release; 2015 Oct; 216():103-10. PubMed ID: 26272765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased NEK2 in hepatocellular carcinoma promotes cancer progression and drug resistance by promoting PP1/Akt and Wnt activation.
    Wen S; Liu Y; Yang M; Yang K; Huang J; Feng D
    Oncol Rep; 2016 Oct; 36(4):2193-9. PubMed ID: 27509921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.